参考文献

2020-10-21

1: Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Review. PubMed PMID: 29748368.

2: Zhou Y, Guo Z, Yan W, Wang W. Cardiovascular effects of sitagliptin --an anti-diabetes medicine. Clin Exp Pharmacol Physiol. 2018 Apr 21. doi: 10.1111/1440-1681.12953. [Epub ahead of print] Review. PubMed PMID: 29679391.

3: Packer M. Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications. JACC Heart Fail. 2018 Mar 1. pii: S2213-1779(18)30041-6. doi: 10.1016/j.jchf.2017.12.016. [Epub ahead of print] Review. PubMed PMID: 29525332.

4: Scheen AJ. The safety of gliptins : updated data in 2018. Expert Opin Drug Saf. 2018 Apr;17(4):387-405. doi: 10.1080/14740338.2018.1444027. Epub 2018 Mar 3. Review. PubMed PMID: 29468916.

5: Palazzuoli A, Ceccarelli E, Ruocco G, Nuti R. Clinical impact of oral antidiabetic medications in heart failure patients. Heart Fail Rev. 2018 May;23(3):325-335. doi: 10.1007/s10741-018-9669-0. Review. PubMed PMID: 29359260.

6: Asleh R, Sheikh-Ahmad M, Briasoulis A, Kushwaha SS. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. Heart Fail Rev. 2018 May;23(3):445-459. doi: 10.1007/s10741-017-9666-8. Review. PubMed PMID: 29270818.

7: Ferrandi EE, Monti D. Amine transaminases in chiral amines synthesis: recent advances and challenges. World J Microbiol Biotechnol. 2017 Dec 18;34(1):13. doi: 10.1007/s11274-017-2395-2. Review. PubMed PMID: 29255954.

8: Coppolino G, Leporini C, Rivoli L, Ursini F, di Paola ED, Cernaro V, Arturi F, Bolignano D, Russo E, De Sarro G, Andreucci M. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res. 2018 Mar;129:274-294. doi: 10.1016/j.phrs.2017.12.001. Epub 2017 Dec 6. Review. PubMed PMID: 29223646.

9: Fixen CW, Fixen DR. Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy. Expert Opin Pharmacother. 2017 Dec;18(18):2001-2006. doi: 10.1080/14656566.2017.1410539. Epub 2017 Dec 1. Review. PubMed PMID: 29172834.

10: Pierelli G, Stanzione R, Forte M, Migliarino S, Perelli M, Volpe M, Rubattu S. Uncoupling Protein 2: A Key Player and a Potential Therapeutic Target in Vascular Diseases. Oxid Med Cell Longev. 2017;2017:7348372. doi: 10.1155/2017/7348372. Epub 2017 Oct 15. Review. PubMed PMID: 29163755; PubMed Central PMCID: PMC5661070.

11: Institute for Quality and Efficiency in Health Care. Dulaglutide (Addendum to Commission A15-07) [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Jun 25. Available from http://www.ncbi.nlm.nih.gov/books/NBK458392/ PubMed PMID: 29144655.

12: Mega C, Teixeira-de-Lemos E, Fernandes R, Reis F. Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes. J Diabetes Res. 2017;2017:5164292. doi: 10.1155/2017/5164292. Epub 2017 Aug 27. Review. PubMed PMID: 29098166; PubMed Central PMCID: PMC5643039.

13: Keshavarz K, Lotfi F, Sanati E, Salesi M, Hashemi-Meshkini A, Jafari M, Mojahedian MM, Najafi B, Nikfar S. Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials. Daru. 2017 Oct 25;25(1):23. doi: 10.1186/s40199-017-0189-6. Review. PubMed PMID: 29070077; PubMed Central PMCID: PMC5655990.

14: Ahmed MH, Husain NE, Elmadhoun WM, Noor SK, Khalil AA, Almobarak AO. Diabetes and Ramadan: A concise and practical update. J Family Med Prim Care. 2017 Jan-Mar;6(1):11-18. doi: 10.4103/2249-4863.214964. Review. PubMed PMID: 29026740; PubMed Central PMCID: PMC5629872.

15: Li M, Yang Y, Jiang D, Ying M, Wang Y, Zhao R. Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2017 Sep;96(39):e8161. doi: 10.1097/MD.0000000000008161. Review. PubMed PMID: 28953663; PubMed Central PMCID: PMC5626306.

16: Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136. Review. PubMed PMID: 28847797.

17: Wu S, Chai S, Yang J, Cai T, Xu Y, Yang Z, Zhang Y, Ji L, Sun F, Zhan S. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clin Ther. 2017 Sep;39(9):1780-1789.e33. doi: 10.1016/j.clinthera.2017.07.036. Epub 2017 Aug 18. Review. PubMed PMID: 28827024.

18: Yang Y, Zhao C, Liang J, Yu M, Qu X. Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms. Front Pharmacol. 2017 Jul 25;8:487. doi: 10.3389/fphar.2017.00487. eCollection 2017. Review. PubMed PMID: 28790917; PubMed Central PMCID: PMC5524773.

19: Seggelke SA, Lindsay MC, Hazlett I, Sanagorski R, Eckel RH, Low Wang CC. Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting. Curr Diab Rep. 2017 Aug;17(8):64. doi: 10.1007/s11892-017-0884-1. Review. PubMed PMID: 28699089.

20: Genovese S, Mannucci E, Ceriello A. A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Adv Ther. 2017 Aug;34(8):1791-1814. doi: 10.1007/s12325-017-0499-6. Epub 2017 Jul 3. Review. PubMed PMID: 28674957; PubMed Central PMCID: PMC5565650.